Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 3, 2015, Pages 242-247

  Tsai, Chiaojung Jillian ^a   Li, Jing ^a   Gonzalez Angulo, Ana M ^a,b   Allen, Pamela K ^a   Woodward, Wendy A ^a   Ueno, Naoto T ^a,b   Lucci, Anthony ^a,b   Krishnamurthy, Savitri ^a,b   Gong, Yun ^a,b   Yang, Wei ^a,b   Cristofanilli, Massimo ^a,b   Valero, Vicente ^a,b   Buchholz, Thomas A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Breast Medical Oncology ^*  (United States)

Author keywords

inflammatory breast cancer; multidisciplinary clinic; survival; targeted therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAXANE DERIVATIVE; BRIDGED COMPOUND; ERBB2 PROTEIN, HUMAN; TAXANE; TAXOID;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; DISEASE FREE SURVIVAL; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; SURVIVAL RATE; TIME; UTILIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MASTECTOMY; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TIME FACTORS; YOUNG ADULT;

EID: 84930756565     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182937921     Document Type: Conference Paper

References (28)

1. Anderson WF, Schairer C, Chen BE, et al. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;22:9-23.
2. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966-975.
3. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22: 4067-4074.
4. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60:351-375.
5. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
6. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686-3696.
7. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
9. Dawood S, Gong Y, Broglio K, et al. Trastuzumab in primary inflammatory breast cancer (IBC): high pathological response rates and improved outcome. Breast J. 2010;16:529-532.
10. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-384.
11. Krutchik AN, Buzdar AU, Blumenschein GR, et al. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979;11:325-332.
12. Gonzalez-Angulo AM, Hennessy BT, Broglio K, et al. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007;12:904-912.
13. Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011;16: 1675-1683.
14. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. Chicago, IL: Springer; 2002.
15. The World Health Organization histological typing of breast tumors-second edition. The World Organization. Am J Clin Pathol. 1982;78:806-816.
16. Bristol IJ, Buchholz TA. Inflammatory breast cancer: current concepts in local management. Breast Dis. 2005;22:75-83.
17. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000; 47:1191-1200.
18. Ballo MT, Strom EA, Prost H, et al. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractio-nated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys. 1999;44:105-112.
19. Woodward WA, Debeb BG, Xu W, et al. Overcoming radiation resistance in inflammatory breast cancer. Cancer. 2010; 116(suppl):2840-2845.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:547-581.
21. Cox D, Oakes N. Analysis of Survival Data. New York: Chapman and Hall; 1984.
22. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005;23:1941-1950.
23. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011;117:1819-1826.
24. Dawood S, Ueno NT, Valero V, et al. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol. 2012;23:870-875.
25. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515-523.
26. Walker GV, Niikura N, Yang W, et al. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012;83:1381-1386.
27. Niikura N, Liu J, Costelloe CM, et al. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist. 2011;16:772-782.
28. Niikura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16: 1111-1119.